Oragenics Inc (NYSEAMERICAN:OGEN) CEO Alan Joslyn updates Proactive Investors on the Florida based biotech's advancements in the last six months.
Joslyn says the company's lead candidate AG013, which treats oral mucositis, resumed its Phase 2 clinical trial of AG013, following a positive review by an independent Data Safety Monitoring Board, with data expected in the middle of 2019. Joslyn says the trial will soon be expanded into 50 centers in the US and into Europe to complete patient enrollment.
Joslyn says the company recently raised $13.8mln to carry the biotech's programs through clinical trials. He says from this point forward most of the work within the company is operational.